Endocrine and bone
Denosumab (RANKL inhibitor)
A monoclonal antibody against RANKL, the signal osteoclasts need to form and survive; a twice-yearly injection for osteoporosis, also used for bone metastases.
Mécanisme d’action
- Osteoblasts and stromal cells express RANKL, which binds RANK on osteoclast precursors and drives their formation and activity.
- Denosumab binds RANKL, mimicking the natural decoy osteoprotegerin.
- Osteoclast formation and bone resorption fall sharply; bone density rises.
- The effect wears off within months, so stopping it causes rapid bone loss unless another drug follows.
Cibles moléculaires
- RANK ligand (RANKL): Neutralised
Médicaments : Denosumab (RANKL inhibitor)
- Denosumab (Subcutaneous injection every six months for osteoporosis; more often for bone metastases.)
Indications thérapeutiques
- Osteoporosis in people at high fracture risk, including those who cannot take bisphosphonates
- Bone loss from androgen deprivation or aromatase inhibitors
- Preventing skeletal events from bone metastases
Maladies traitées
Effets indésirables
- Hypocalcaemia
- Skin infections and eczema
- Osteonecrosis of the jaw and atypical femoral fractures (rare)
- Multiple vertebral fractures after stopping without follow-on treatment
Contre-indications selon le terrain
- Hypocalcaemia (Contre-indiqué): It lowers calcium further; vitamin D and calcium are corrected first.
- Severe kidney impairment (Avec précaution): Hypocalcaemia is more common and severe, though the drug is not cleared by the kidney.
Sujets liés
Rédigé d’après
- Lippincott Illustrated Reviews: Pharmacology, 7th ed., Ch. 27, Drugs Affecting Bone Metabolism, Denosumab
- Basic & Clinical Pharmacology (Katzung), 14th ed., Ch. 42, Agents That Affect Bone Mineral Homeostasis, Denosumab
Ressource pédagogique. Ne constitue pas un avis, un diagnostic ou un traitement médical.